(NASDAQ: TBPH) Theravance Biopharma's forecast annual revenue growth rate of 19.98% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Theravance Biopharma's revenue in 2025 is $64,381,000.On average, 3 Wall Street analysts forecast TBPH's revenue for 2025 to be $4,793,854,106, with the lowest TBPH revenue forecast at $4,756,108,003, and the highest TBPH revenue forecast at $4,826,851,028. On average, 3 Wall Street analysts forecast TBPH's revenue for 2026 to be $4,167,555,715, with the lowest TBPH revenue forecast at $4,106,063,701, and the highest TBPH revenue forecast at $4,240,129,154.
In 2027, TBPH is forecast to generate $5,893,240,295 in revenue, with the lowest revenue forecast at $5,638,169,639 and the highest revenue forecast at $6,352,525,781.